{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:28:07Z","timestamp":1786548487572,"version":"build-2736575974"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody\u2013drug conjugates (ADCs) are a rapidly growing class of targeted therapeutics designed to deliver potent payloads while minimizing systemic toxicity. Despite significant progress, all approved ADCs are administered intravenously (IV). In contrast, subcutaneous (SC) delivery is well established for antibodies, offering shorter administration time, improved convenience, and the potential for outpatient or home-based treatment. Extending SC delivery to ADCs is therefore attractive but introduces unique challenges related to structural complexity, linker\u2013payload instability, and cytotoxic payloads.<\/jats:p>\n                  <jats:p>This review evaluates the feasibility of subcutaneously administered ADCs by integrating insights from pharmacokinetic and pharmacodynamic studies, emerging clinical data, and advances in molecular design, formulation, and delivery technologies. Key challenges include limited clinical comparisons between IV and SC routes, uncertain bioavailability and tumor exposure, linker\u2013payload instability, injection-site reactions, and high-concentration formulation constraints. Enabling strategies, such as rational molecular design, hyaluronidase-enabled delivery, polymer-based systems, and conversion of IV ADCs to SC dosing, are discussed.<\/jats:p>\n                  <jats:p>Recent advances, exemplified by JSKN033, demonstrate the feasibility of high-concentration liquid co-formulation approaches for SC administration and may represent a future direction. Evidence across oncology and non-oncology programs suggests that while SC delivery is achievable, success is highly molecule dependent. Overall, transitioning ADCs from IV to SC requires case-by-case evaluation and coordinated innovation across rational molecular design, formulation, and nonclinical and clinical development to realize the full patient-centric benefits of this approach.<\/jats:p>","DOI":"10.1093\/abt\/tbag028","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:23:27Z","timestamp":1780313007000},"page":"395-406","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous administration of antibody\u2013drug conjugates: current challenges, emerging opportunities, and future perspectives"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9425-0183","authenticated-orcid":false,"given":"Steven","family":"Ren","sequence":"first","affiliation":[{"name":"Bioproduct Research and Development, Eli Lilly and Company , Indianapolis, IN 46285 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn Shouye","family":"Wang","sequence":"additional","affiliation":[{"name":"Business Enablement North America, XDC ConjuTech USA LLC , Middletown, DE 19709 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Yunsong","family":"Li","sequence":"additional","affiliation":[{"name":"Bioproduct Research and Development, Eli Lilly and Company , Indianapolis, IN 46285 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026081210262867400_ref1","volume-title":"Antibody Therapeutics Product Data"},{"key":"2026081210262867400_ref2","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"2026081210262867400_ref3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0148607116676593","article-title":"Subcutaneous infusion of fluids for hydration or nutrition: a review","volume":"42","author":"Caccialanza","year":"2018","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2026081210262867400_ref4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.revmed.2025.11.002","article-title":"Subcutaneous infusion: indications, practical considerations, and tolerability","volume":"47","author":"Arcani","year":"2026","journal-title":"Rev Med Interne"},{"key":"2026081210262867400_ref5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/abt\/tbab027","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antibody Therapeutics"},{"key":"2026081210262867400_ref6","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J Pharm Sci"},{"key":"2026081210262867400_ref7"},{"key":"2026081210262867400_ref8","doi-asserted-by":"publisher","first-page":"103877","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J Pharm Sci"},{"key":"2026081210262867400_ref9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00280-013-2289-4","article-title":"An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs","volume":"72","author":"Launay-Vacher","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026081210262867400_ref10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/abt\/tbaf005","article-title":"Fundamental properties and principal areas of focus in antibody\u2013drug conjugates formulation development","volume":"8","author":"Wen","year":"2025","journal-title":"Antibody Therapeutics"},{"key":"2026081210262867400_ref11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tbae030","article-title":"Practical advice in the development of a lyophilized protein drug product","volume":"8","author":"Cheng","year":"2024","journal-title":"Antib Ther"},{"key":"2026081210262867400_ref12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates administered via subcutaneous and Intratumoral routes","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026081210262867400_ref13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10928-025-09978-3","article-title":"A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates","volume":"52","author":"Chang","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026081210262867400_ref14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers."},{"key":"2026081210262867400_ref15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"S\u00e1nchez-F\u00e9lix","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"2026081210262867400_ref16","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1002\/jcph.1720","article-title":"Impact of physiologically based pharmacokinetics, population pharmacokinetics and pharmacokinetics\/pharmacodynamics in the development of antibody-drug conjugates","volume":"60 Suppl 1","author":"Li","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2026081210262867400_ref17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cancers18010005","article-title":"Pharmacokinetic and Pharmacodynamic Modeling of antibody-drug conjugates","volume":"18","author":"Glassman","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026081210262867400_ref18","doi-asserted-by":"publisher","first-page":"Abstract 1523","DOI":"10.1158\/1538-7445.AM2023-1523","article-title":"Subcutaneous dosing of amatoxin-based ADCs increases the therapeutic index [abstract]. In: proceedings of the American Association for Cancer Research annual meeting 2023","volume":"83","author":"Decker","year":"2023","journal-title":"Cancer Res"},{"key":"2026081210262867400_ref19"},{"key":"2026081210262867400_ref20","volume-title":"Poster, 2024 Society for Immunotherapy of Cancer. 39th Annual Meeting & Pre-Conference, Nov. 6\u201310, 2024","author":"Lemech"},{"key":"2026081210262867400_ref21","doi-asserted-by":"publisher","first-page":"A1684","DOI":"10.1136\/jitc-2024-SITC2024.1496","article-title":"JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of Biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor. Abstract 1496","volume":"12","author":"Lemech","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026081210262867400_ref22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/ol.2025.15396","article-title":"Adverse events induced by the subcutaneous HER2-targeted antibody-drug conjugate JSKN033 in a male patient with breast cancer: a case report","volume":"31","author":"Yang","year":"2025","journal-title":"Oncol Lett"},{"key":"2026081210262867400_ref23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10637-022-01287-7","article-title":"Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"40","author":"Shimizu","year":"2022","journal-title":"Invest New Drugs"},{"key":"2026081210262867400_ref24","doi-asserted-by":"publisher","first-page":"e13138","DOI":"10.1200\/JCO.2025.43.16_suppl.e13138","article-title":"Abstract e13138. First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results","volume":"43","author":"Yao","year":"2025","journal-title":"ASCO Annual Meeting abstract, JCO"},{"key":"2026081210262867400_ref25","doi-asserted-by":"publisher","first-page":"1556245","DOI":"10.3389\/fphar.2025.1556245","article-title":"Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026081210262867400_ref26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jconrel.2020.08.013","article-title":"Advancements in the co-formulation of biologic therapeutics","volume":"327","author":"Chauhan","year":"2020","journal-title":"J Control Release"},{"key":"2026081210262867400_ref27","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2023-SITC2023.1157","article-title":"GQ1007: the next generation HER2-targeting antibody immune agonist conjugate with robust efficacy and favorable safety profile. Abstract 1157","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026081210262867400_ref28"},{"key":"2026081210262867400_ref29","article-title":"Alteogen Confirms Safety Improvement in Subcutaneous ADC, to Present Results in June\u2014Seoul Economic Daily","author":"Hyo-jung","year":"2026"},{"key":"2026081210262867400_ref30","volume-title":"American Society for Clinical Pharmacology and Therapeutics. 2026 Annual Meeting, Gaylord Rockies","author":"Kim"},{"key":"2026081210262867400_ref31","doi-asserted-by":"publisher","first-page":"105745","DOI":"10.1016\/j.esmoop.2025.105745","article-title":"169P subcutaneous administration of antibody-drug-conjugates","volume":"10","author":"Detappe","year":"2025","journal-title":"ESMO Open, Abstract 169P"},{"key":"2026081210262867400_ref32","volume-title":"Subcutaneous Administration of Antibody-Drug Conjugates for Cancer Therapy. US10799597B2","author":"Goldenberg","year":"2018"},{"key":"2026081210262867400_ref33","volume-title":"Subcutaneous Administration of Antibody-Drug Conjugates for Cancer Therapy. WO 2018\/187074A1","author":"Goldenberg","year":"2018"},{"key":"2026081210262867400_ref34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-025-02226-5","article-title":"Trastuzumab Rezetecan: First approval","volume":"86","author":"Hoy","year":"2025","journal-title":"Drugs"},{"key":"2026081210262867400_ref35","doi-asserted-by":"publisher","first-page":"e0326691","DOI":"10.1371\/journal.pone.0326691","article-title":"SHR-A1811, a novel anti-HER2 antibody\u2013drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles","volume":"20","author":"Zhang","year":"2025","journal-title":"PloS One"},{"key":"2026081210262867400_ref36","volume-title":"Pertuzumab Zuvotolimod\/SBT6050. ADC Review"},{"key":"2026081210262867400_ref37","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2020-SITC2020.0317","article-title":"A phase 1\/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like recepter 8 agonist, in subjects with advanced HER2-expressing solid tumors. Abstract 317","volume":"8","author":"Emens","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026081210262867400_ref38","doi-asserted-by":"publisher","first-page":"S450","DOI":"10.1016\/j.annonc.2021.08.491","article-title":"Interim results of a phase I\/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. Abstract 209P","volume":"32","author":"Klempner","year":"2021","journal-title":"Ann Oncol"},{"key":"2026081210262867400_ref39","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2021-SITC2021.393","article-title":"A phase 1\/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers. Abstract 393","volume":"9","author":"Klempner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026081210262867400_ref40","volume-title":"Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results","year":"2022"},{"key":"2026081210262867400_ref41","doi-asserted-by":"publisher","first-page":"15893","DOI":"10.1021\/acs.jmedchem.2c01579","article-title":"Discovery of ABBV-3373, an anti-TNF glucocorticoid receptor modulator immunology antibody drug conjugate","volume":"65","author":"Hobson","year":"2022","journal-title":"J Med Chem"},{"key":"2026081210262867400_ref42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.42415","article-title":"Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase IIa trial","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026081210262867400_ref43","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1021\/acs.jmedchem.3c00794","article-title":"Optimization of drug-linker to enable long-term storage of antibody\u2013drug conjugate for subcutaneous dosing","volume":"66","author":"Hobson","year":"2023","journal-title":"J Med Chem"},{"key":"2026081210262867400_ref44","doi-asserted-by":"publisher","first-page":"117576","DOI":"10.1016\/j.ejmech.2025.117576","article-title":"Advances and challenges in immunosuppressive antibody drug conjugates","volume":"291","author":"Yaseen","year":"2025","journal-title":"Eur J Med Chem"},{"key":"2026081210262867400_ref45","doi-asserted-by":"publisher","first-page":"12544","DOI":"10.1021\/acs.jmedchem.3c01174","article-title":"Discovery of ABBV-154, an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (iADC)","volume":"66","author":"Hobson","year":"2023","journal-title":"J Med Chem"},{"key":"2026081210262867400_ref46","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/art.43129","article-title":"Efficacy, safety, pharmacokinetics, and immunogenicity of ABBV-154 in adults with glucocorticoid-dependent polymyalgia Rheumatica: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"77","author":"Spiera","year":"2025","journal-title":"Arthritis Rheum"},{"key":"2026081210262867400_ref47","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/art.43266","article-title":"Efficacy and safety of ABBV-154 for the treatment of active rheumatoid arthritis: a phase 2b, randomized, placebo-controlled trial","volume":"77","author":"Buttgereit","year":"2025","journal-title":"Arthritis & rheumatology"},{"key":"2026081210262867400_ref48","article-title":"Abstract 0494. LFD-200, an antibody drug conjugate that selectively delivers a glucocorticoid payload to immune cells, provides sustained anti-inflammatory effects without systemic toxicity in non-human primates","volume":"77","author":"McClure","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026081210262867400_ref49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40495-026-00442-5","article-title":"Subcutaneous Administration of Antibody-drug Conjugates","volume":"12","author":"Yaseen","year":"2026","journal-title":"Curr Pharmacol Rep"},{"key":"2026081210262867400_ref50","doi-asserted-by":"publisher","first-page":"e16429","DOI":"10.1002\/adma.202516429","article-title":"High-concentration antibody formulation via solvent-based dehydration","volume":"38","author":"Zheng","year":"2026","journal-title":"Adv Mater"},{"key":"2026081210262867400_ref51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13346-025-01856-2","article-title":"S.C. Delivery of ultra-high concentration (up to 500 mg\/ml) protein microparticle suspensions: pharmacokinetics, efficacy, biodistribution, and immunogenicity. Drug Deliv","volume":"16","author":"Shadbar","year":"2026","journal-title":"Transl Res"},{"key":"2026081210262867400_ref52","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/ph19030393","article-title":"Formulation matters: the overlooked engine of stability and success in antibody-drug conjugates","volume":"19","author":"Torres-Dias","year":"2026","journal-title":"Pharmaceuticals."},{"key":"2026081210262867400_ref53","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody\u2013drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026081210262867400_ref54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and tolerability of antibody-drug conjugates in cancer","volume":"42","author":"Wolska-Washer","year":"2019","journal-title":"Drug Saf"},{"key":"2026081210262867400_ref55","doi-asserted-by":"publisher","first-page":"114941","DOI":"10.1016\/j.jconrel.2026.114941","article-title":"Engineering the subcutaneous delivery of antibody-drug conjugates","volume":"395","author":"Detappe","year":"2026","journal-title":"J Control Release"},{"key":"2026081210262867400_ref56","doi-asserted-by":"publisher","first-page":"113610","DOI":"10.1016\/j.eurpolymj.2024.113610","article-title":"Injectable hydrogel formulations: design, synthesis and applications for subcutaneous delivery\u2014a comprehensive review","volume":"222","author":"Sarvepalli","year":"2025","journal-title":"Eur Polym J"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag028\/68457697\/tbag028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/395\/68457697\/tbag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/395\/68457697\/tbag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:27:38Z","timestamp":1786544858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/3\/395\/8700359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag028","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,3]]}}}